BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ielasi L, Tovoli F, Tonnini M, Tortora R, Magini G, Sacco R, Pressiani T, Trevisani F, Sansone V, Marasco G, Piscaglia F, Granito A. Beneficial Prognostic Effects of Aspirin in Patients Receiving Sorafenib for Hepatocellular Carcinoma: A Tale of Multiple Confounders. Cancers (Basel) 2021;13:6376. [PMID: 34944996 DOI: 10.3390/cancers13246376] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Huang K, Lee P, Chao Y, Su C, Lee I, Lan K, Chu C, Hung Y, Chen S, Hou M, Huang Y. Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma. Ther Adv Med Oncol 2022;14:175883592210994. [DOI: 10.1177/17588359221099401] [Reference Citation Analysis]
2 Sung F, Yeh Y, Muo C, Hsu C, Tsai W, Hsu Y. Statins Reduce Hepatocellular Carcinoma Risk in Patients with Chronic Kidney Disease and End-Stage Renal Disease: A 17-Year Longitudinal Study. Cancers 2022;14:825. [DOI: 10.3390/cancers14030825] [Reference Citation Analysis]